YIH
AMPE

Y-Intercept (HK)’s Ampio Pharmaceuticals Inc. AMPE Stock Holding History

Y-Intercept (HK)’s Portfolio AMPE Stock Details AMPE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-92
Closed -$5K – 1375
2022
Q2 		$5K Buy
+92
New +$6.85K ﹤0.01% 824

Other funds holding AMPE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
PCMC
Private Capital Management (Colorado) Denver, Colorado $501M AUM 17.09% 1-Year Est. Return
SA
Shilanski & Associates Anchorage, Alaska $376M AUM 19.08% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Courier Capital Buffalo, New York $2B AUM 24.36% 1-Year Est. Return

Y-Intercept (HK)'s AMPE Position: Q3 2022 in Review

Y-Intercept (HK) sold out of Ampio Pharmaceuticals Inc. (AMPE) in Q3 2022, closing a stake of 92 shares — an estimated $5K sold.

Y-Intercept (HK) first reported a position in AMPE in Q2 2022 and held it in 1 quarter. The position peaked at $5K in Q2 2022. 95 funds tracked by Wall St. Rank hold AMPE as of Q3 2022.

  • Y-Intercept (HK) reported no remaining Ampio Pharmaceuticals Inc. position as of Q3 2022 after selling out during the quarter.
  • Y-Intercept (HK) sold 92 Ampio Pharmaceuticals Inc. shares in Q3 2022, an estimated $5K.
  • Y-Intercept (HK) first reported a position in Ampio Pharmaceuticals Inc. in Q2 2022 and held it in 1 quarter.
  • Y-Intercept (HK)'s Ampio Pharmaceuticals Inc. position peaked at $5K in Q2 2022.
  • 95 funds tracked by Wall St. Rank held Ampio Pharmaceuticals Inc. as of Q3 2022.

Based on Y-Intercept (HK)'s 13F filing for Q3 2022, filed 14 Feb 2023.